Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.37 |
| ▸ | TNKS | O95271 | 2/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 8/20 | 0.33 |
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3926065 | 0.86 | PIK3CB (0.36) | SUV39H2SMOPIK3CBCCNE1CDK2 | |
| SCHEMBL3926820 | 0.84 | KDM5B (0.40) | CDK2 | |
| SCHEMBL3921414 | 0.84 | CCNE1 (0.32) | SUV39H2CCNE1CDK2 | |
| SCHEMBL3926786 | 0.84 | CKS1B (0.39) | CCNE1CDK2 | |
| SCHEMBL3932218 | 0.82 | DKK1 (0.36) | SUV39H2PIK3CBCCNE1CDK2 | |
| SCHEMBL3923615 | 0.81 | PAK1 (0.40) | — | |
| SCHEMBL3931683 | 0.81 | JAK2 (0.48) | JAK2CCNE1CDK2 | |
| SCHEMBL3923740 | 0.80 | SMO (0.40) | SUV39H2SMO | |
| SCHEMBL3933854 | 0.79 | DKK1 (0.43) | — | |
| SCHEMBL916719 | 0.79 | POLB (0.36) | JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051980-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| US-7531539-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, NTRK2, NTRK3 | SUV39H2 3296/4885TNKS 259/4885SMYD3 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.